Eagle Pharmaceuticals (EGRX) 8-K Changes in Registrant's Certifying Accountant

Exhibit 16.1

October 1, 2020

Securities and Exchange Commission 

100 F Street N.E. 

Washington, D.C. 20549

We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 25, 2020, to be filed by our former client, Eagle Pharmaceuticals, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm.

Very truly yours,

/s/ BDO USA, LLP